Background: Acinetobacter species are associated with high mortality, with A. baumannii being associated with a significant number of hospitals acquired infections worldwide. Multidrug resistance makes it challenging to control or treat these infections. Aim of this study is to evaluate the risk factors and compare the clinical outcomes of Acinetobacter infections in a tertiary care hospital, in COVID and non COVID patients. Materials and methods:A retrospective observational study was conducted. A list of all cases with positive cultures of A. baumannii over a period of one year (January 2020 and December 2020) was retrieved from the microbiology department, using hospital database. The risk factors, antibiotic resistance and clinical outcomes were studied.Results: 94 cases of A. baumannii infections were studied. 89 were caused by Multidrug resistant A. baumannii including carbapenem resistant A. baumannii (CRAB) (92.7%). All were sensitive to Colistin. 28 patients had COVID-19 infection with a mortality rate of 85.7% (p = 0.009). Various risk factors associated with higher mortality were higher age, Intubation (p = 0.004), male sex (p = 0.023), invasive procedures (p = 0.0001) and carbapenem resistance (p = 0.033). Conclusion: COVID-19 infection increased the risk ofAcinetobacter infections. Carbapenem resistance and invasive procedures were associated with higher mortality rates. Judicious use of antibiotics with proper infection control practices and early diagnosis could be pivotal in preventing prevalence of Acinetobacter infections in the current pandemic situation.